Search our Database of Scientific Publications and Authors

I’m looking for a

    3840 results match your criteria Alopecia Areata

    1 OF 77

    Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.
    Janus kinase inhibitors are emerging treatment alternatives in various immune-mediated diseases including alopecia universalis. Herein, we report a patient with psoriasis and alopecia universalis in whom treatment with tofacitinib led to remission of psoriasis without improvement in alopecia universalis. Despite the promising potential in alopecia areata treatment, research evaluating the efficacy of different Janus kinase inhibitors and possible prognostic factors related with a more favorable response are warranted. Read More

    Adalimumab-related alopecia in a patient affected by psoriasis.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.
    Alopecia induced by biological therapy is a rare side effect of this type of drugs. A total of 23 patients of psoriasiform eruptions with severe scalp involvement that induced alopecia during anti-tumor necrosis factor (anti-TNF) treatment of non-dermatological conditions have been previously reported. We present a 50-year-old man affected by plaque psoriasis that developed psoriasiform patches with alopecia over his scalp 10 months after initiating treatment with adalimumab. Read More

    EMERGING DRUGS FOR ALOPECIA AREATA: JAK INHIBITORS.
    Expert Opin Emerg Drugs 2018 Feb 21. Epub 2018 Feb 21.
    b Fredric Brandt Endowed Professor of Dermatology - Miller School of Medicine , University of Miami (FL) , USA.
    Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Read More

    Study of the efficacy of carboxytherapy in alopecia.
    J Cosmet Dermatol 2018 Feb 20. Epub 2018 Feb 20.
    Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.
    Background: Management of alopecia areata (AA) and androgenetic alopecia (AGA) is often challenging. The use of carboxytherapy may be a novel therapeutic option for such cases.

    Objective: To evaluate the clinical efficacy and safety of carboxytherapy in alopecia areata and androgenetic alopecia. Read More

    An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis.
    J Invest Dermatol 2018 Feb 13. Epub 2018 Feb 13.
    Department of Dermatology. Electronic address:
    Alopecia areata (AA) is a common autoimmune disease, with a lifetime risk of ∼2%. In AA, the immune systems targets the hair follicle, resulting in clinical hair loss. AA prognosis is unpredictable, and currently there is no definitive treatment. Read More

    Use of an Alternating Inflatable Head Pad inPatients Undergoing Open Heart Surgery.
    Med Sci Monit 2018 Feb 16;24:970-976. Epub 2018 Feb 16.
    Department of Nursing, Yantai Yuhuangding Hospital, Yantai, Shandong, China (mainland).
    BACKGROUND Preoperative symptoms like occipital pressure ulcers and alopecia areata (AA) significantly lowered patient quality of life. Therefore, preoperative nursing was in need of investigation. This study aimed to compare effects of an alternating inflatable head pad and a gel pad on occurrence of postoperative pressure ulcers and AA in patients undergoing open heart surgery. Read More

    Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study.
    Dermatol Ther (Heidelb) 2018 Mar 13;8(1):101-110. Epub 2018 Feb 13.
    Dermatology Department of Centro Medico Polispecialistico, Pavia, Italy.
    Introduction: Topical immunotherapy is frequently used in the treatment of alopecia areata (AA) although few studies report long-term follow-up. Our goals were to determine the efficacy and the prognostic factors of topical immunotherapy in a large cohort of patients with AA treated in the departments of Dermatology and Venereology of Bergamo, Como and Pavia, from 1978 to January 2016.

    Methods: A total of 252 patients with AA were evaluated retrospectively. Read More

    Three Cases of Radiation-induced Temporary Alopecia with Hair Microscopic Examination: "Coudability Hair" Might Not be Specific for Alopecia Areata.
    Int J Trichology 2018 Jan-Feb;10(1):40-43
    Department of Dermatology, Busan Paik Hospital, Busan, Korea.
    Endovascular interventional procedures are widely used for the treatment of intracranial vascular lesions. However, they sometimes produce reversible alopecia, known as radiation-induced temporary alopecia, depending on the radiation dose. Radiation-induced temporary alopecia manifested as rectangular alopecic patches without signs of inflammation, reflects damage to the keratinocytes in the hair matrix of anagen hair follicles, due to the sensitivity of these cells to radiation. Read More

    Annular Alopecia Areata: A Morphologically Rare Variant.
    Int J Trichology 2018 Jan-Feb;10(1):34-36
    Department of Dermatology and Venereology, Government Medical College and Hospital, Chandigarh, India.
    Alopecia areata (AA) is the most common form of nonscarring alopecia involving the scalp and/or body. The most common pattern of hair loss is oval or round, but newer morphological variants are increasingly being described. We hereby report two cases of annular pattern of AA due to its unusual morphology. Read More

    Development of Frontal Fibrosing Alopecia with a History of Alopecia Areata.
    Int J Trichology 2018 Jan-Feb;10(1):29-30
    Department of Dermatology, University of California, Irvine, Irvine, California.
    Frontal fibrosing alopecia (FFA), a scarring type of alopecia, developed in two patients with a history of alopecia areata (AA). Both patients had biopsies to confirm this interesting series of pathology. Etiology and pathogenesis of this AA-to-FFA sequence will be discussed. Read More

    Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide.
    Int J Dermatol 2018 Jan 29. Epub 2018 Jan 29.
    Division of Clinical Dermatology, Mayo Clinic, Rochester, MN, USA.
    Understanding the effects of age on the epidemiology of diseases primarily affecting the skin is important to the practice of dermatology, both for proper allocation of resources and for optimal patient-centered care. To fully appreciate the effect that age may have on the population-based calculations of incidence of diseases primarily affecting the skin in Olmsted County, Minnesota, and worldwide, we performed a review of all relevant Rochester Epidemiology Project-published data and compared them to similar reports in the worldwide English literature. Using the Rochester Epidemiology Project, population-based epidemiologic studies have been performed to estimate the incidence of specific skin diseases over the past 50 years. Read More

    Impact of climate change on dermatological conditions related to flooding: update from the International Society of Dermatology Climate Change Committee.
    Int J Dermatol 2018 Jan 29. Epub 2018 Jan 29.
    Department of Dermatology, Mayo Clinic in Minnesota, Rochester, Minnesota, USA.
    Climate change contributes to the increase in severity and frequency of flooding, which is the most frequent and deadly disaster worldwide. Flood-related damage can be very severe and include health effects. Among those health impacts, dermatological diseases are one of the most frequently encountered. Read More

    Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies.
    J Health Psychol 2018 Jan 1:1359105317752826. Epub 2018 Jan 1.
    Leiden University, The Netherlands.
    Applying the Common Sense Model, this cross-sectional study examines associations between illness perceptions and quality of life and the mediating role of coping in 243 adults with alopecia areata, a chronic dermatological condition. At least some QoL impairment was reported by 84 percent of participants, with 31 percent reporting very to extremely large impairment. Stronger perceptions of consequences, emotional representations, identity, and lower attribution to chance were related to more impairment, with avoidant coping acting as (partial) mediator. Read More

    Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata.
    J Clin Lab Anal 2018 Jan 18. Epub 2018 Jan 18.
    Department of Medical Biology, Medical Faculty, Gaziosmanpasa University, Tokat, Turkey.
    Background: Alopecia areata (AA), which appears as nonscarring hair shedding on any hair-bearing area, is a common organ-specific autoimmune condition. Cytokines have important roles in the development of AA. Interleukin (IL) 18 is a significant proinflammatory cytokine that was found higher in the patients with AA. Read More

    Is there an association of ABO blood groups and Rhesus factor with alopecia areata?
    J Cosmet Dermatol 2018 Jan 15. Epub 2018 Jan 15.
    Department of Dermatology, Faculty of Medicine, Selcuk University, Konya, Turkey.
    Background/objectives: Alopecia areata (AA) is an autoimmune disease characterized by noncicatricial hair loss localized on hair, beard, mustache, eyebrow, eyelash, and sometimes on the body. Although etiopathogenesis is not fully understood, many studies show remarkable associations between various diseases and ABO blood groups. However, there is no study with AA and blood groups. Read More

    Childhood alopecia areata-Data from the National Alopecia Areata Registry.
    Pediatr Dermatol 2018 Jan 15. Epub 2018 Jan 15.
    Department of Dermatology, MD Anderson Cancer Center, Houston, TX, USA.
    Background/objectives: Alopecia areata may occur at any age and is the third-most-common dermatosis in children. The objective of this study was to investigate the clinical and epidemiologic features of children and adolescents with alopecia areata based on the data of the National Alopecia Areata registry on children and adolescents.

    Methods: Two thousand two hundred eighteen children and adolescents with alopecia areata self-enrolled in the National Alopecia Areata Registry and completed a web-based, self-administered, short-intake screening questionnaire (first tier). Read More

    Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata.
    Sci Rep 2018 Jan 11;8(1):521. Epub 2018 Jan 11.
    Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
    Alopecia areata (AA) is one of the common hair disorders for which treatment is frequently ineffective and associated with relapsing episodes. Better understanding of disease mechanisms and novel therapeutic targets are thus required. From 10 AA patients, quantitative proteomics using LTQ-Orbitrap-XL mass spectrometer revealed 104 down-regulated, 4 absent, 3 up-regulated and 11 newly present proteins in lesional vs. Read More

    Nail changes in alopecia areata: an update and review.
    Int J Dermatol 2018 Jan 10. Epub 2018 Jan 10.
    Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
    Nail changes are a common feature of alopecia areata (AA) and are a significant source of cosmetic disfigurement and functional impairment. This review provides an update of the prevalence, clinical and histopathological features, pathogenesis, differential diagnosis, clinical course, prognosis, and management of nail changes in patients with AA. Searches for peer-reviewed journal articles were conducted using the PubMed/MEDLINE database with the search terms "nail changes alopecia areata," "alopecia areata nails," and specific searches on "trachyonychia alopecia areata" and "pitting alopecia areata. Read More

    Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27.
    Ophthalmic Surg Lasers Imaging Retina 2018 Jan;49(1):60-63
    A 12-year-old Indian boy presented with acute and severe vision loss in his right eye. He was being treated for scalp alopecia areata and rashes behind the ears and above the brow. The eye examination revealed unilateral hemorrhagic retinal vasculitis. Read More

    A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata.
    Dermatol Reports 2017 Oct 30;9(2):7399. Epub 2017 Nov 30.
    Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
    Diphenylcyclopropenone (DPCP) is an effective topical immunotherapy for recalcitrant alopecia areata (AA), which sometimes requires prolonged treatment. We developed a new treatment protocol to shorten the duration of therapy. This study aimed to compare the efficacy and safety of the new treatment protocol with the standard treatment protocol in the treatment of recalcitrant AA. Read More

    Naked Hair Shafts as a Marker of Cicatricial Alopecia.
    Am J Dermatopathol 2017 Dec 28. Epub 2017 Dec 28.
    Departments of Dermatology, and.
    Naked hair shafts (NHS) are free-floating hair shafts devoid of surrounding epithelium, supporting structures, and/or embedded in inflammation that may result from destruction of hair follicles by scarring processes such as inflammation and fibroplasia. Extensive examination of NHS has not been performed in scalp biopsies of alopecia. We retrospectively evaluated 622 scalp biopsies of alopecia [345 cicatricial alopecias (central centrifugal cicatricial alopecia, lichen planopilaris, discoid lupus erythematosus, acne keloidalis nuchae, and folliculitis decalvans] and 277 non-cicatricial alopecias [alopecia areata, androgenic alopecia, telogen effluvium, and psoriatic alopecia)] for the presence of NHS. Read More

    Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients.
    J Eur Acad Dermatol Venereol 2017 Dec 28. Epub 2017 Dec 28.
    Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.
    Background: Alopecia areata (AA) is an organ-specific autoimmune disease with T-cell-mediated attack of hair follicle autoantigens. As T helper 17 (Th17) cells and T regulatory (Treg) cells are crucially involved in the pathogenesis, the role of Th17 and Treg cytokines has not been studied yet.

    Objective: To determine whether AA is associated with alterations in lesional and serum Th17 and Treg cytokines and studied whether they were associated with clinical type. Read More

    Alopecia Areata: The Clinical Situation.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S9-S11
    Department of Dermatology, University of Minnesota Medical School, Minneapolis, Minnesota, USA. Electronic address:
    In the absence of an approved treatment by the US Food and Drug Administration, choosing one of the many off-label treatments available for a child, teen, or adult with alopecia areata (AA) can be challenging. The physician or midlevel provider treating a patient with AA needs to take into consideration the age of the patient, location of hair loss, disease extent and activity, and any ongoing medical or psychological issues. Many patients and their families have now also heard the "buzz" about evolving research, particularly with JAK inhibitors, for the treatment of AA. Read More

    Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S62-S64
    Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA; Department of Genetics and Genomics Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA; The Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
    Alopecia areata is a T-cell-mediated disease that shares phenotypic similarities with other inflammatory diseases, particularly atopic dermatitis, and lacks safe, effective, mechanism-specific treatments. Increasing data suggests that alopecia areata harbors contributions of T helper type 1, T helper type 2, T helper type 17/IL-23, and phosphodiesterase pathways. Antagonism of these axes is undergoing evaluation, and might elucidate the underlying molecular circuitry of alopecia areata, advancing the translational revolution for this disease. Read More

    Big Data Reveal Insights into Alopecia Areata Comorbidities.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S57-S61
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA; Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, New York, USA. Electronic address:
    Autoimmune diseases create a substantial burden of disease, and alopecia areata is among the more prevalent forms. Comorbidities are medical conditions that tend to occur together and may provide etiologic insights, suggest novel therapeutic strategies, and help patients and family members understand the risk of other health conditions. It is well established that having one autoimmune disease increases risk for others because of an underlying shared biology. Read More

    Why Finding a Treatment for Alopecia Areata Is Important: A Multifaceted Perspective.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S51-S53
    Family Medicine, Contra Costa Regional Medical Center, Martinez, California, USA. Electronic address:
    Alopecia areata is an autoimmune disease that alters one's appearance. Some define it as a cosmetic disease despite evidence that substantial psychosocial burden is associated with it. As a physician, support group leader, consultant for the National Alopecia Areata Foundation, and patient, I discuss the evidence behind the psychosocial impact of alopecia areata and the importance of comprehensive treatment. Read More

    Race and Alopecia Areata amongst US Women.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S47-S50
    Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
    Few studies have examined the clinical epidemiology of alopecia areata (AA) in regard to patient race, and therefore, any disparities in incidence or prevalence of disease are largely unexplored. We sought to investigate potential racial disparities amongst two large cohorts of women. We conducted a cross-sectional analysis from the Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII), wherein participants self-reported a diagnosis of AA. Read More

    The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S41-S46
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Alopecia areata (AA) is an autoimmune disease that causes hair loss. Although persons with the disease can be physically described as having varying degrees of hair loss, the condition has significant ramifications on an individual's well-being. We previously reported the preliminary psychometric properties of the Alopecia Areata Symptom Impact Scale (AASIS), a disease-specific measure that asks participants about their AA symptoms and how these symptoms interfere with their daily functioning. Read More

    Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S34-S40
    Division of Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Departments of Pediatrics and Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address:
    Quantifying alopecia areata in real time has been a challenge for clinicians and investigators. Although several scoring systems exist, they can be cumbersome. Because there are more clinical trials in alopecia areata, there is an urgent need for a quantitative system that is reproducible, standardized, and simple. Read More

    Emerging Unconventional Therapies for Alopecia Areata.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S32-S33
    Department of Dermatology, University of California, Irvine, California, USA. Electronic address:
    Alopecia areata is a prevalent autoimmune skin disease with no cure or indicated treatment options. In the absence of an approved treatment, some patients are eager to try unconventional therapies, despite the very limited research evaluating their safety and efficacy. Recently emerging unconventional therapies for alopecia areata discussed include antihistamines, cryotherapy, and low-dose naltrexone. Read More

    Building and Crossing the Translational Bridge: 2016 Alopecia Areata Research Summit Highlights.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S3-S8
    Department of Medicine, Division of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
    Alopecia areata (AA) is a common autoimmune skin disease that results in the loss of hair on the scalp and elsewhere on the body and affects over 146 million people worldwide at some point in their lives. Founded in 1981, the National Alopecia Areata Foundation is a nonprofit organization that supports research to find a cure or acceptable treatment for AA, supports those with the disease, and educates the public about AA. The National Alopecia Areata Foundation conducts research summits every 2 years to review progress and create new directions in its funded and promoted research. Read More

    Treatment of Alopecia Areata with Simvastatin/Ezetimibe.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S25-S31
    University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida, USA. Electronic address:
    Alopecia areata (AA) is an autoimmune disorder characterized by T lymphocytic infiltrates around the bulbar region of hair follicles. Statins have surfaced as potential therapeutic agents for AA, partly because of their modulation of the JAK/STAT pathway. Some data indicate that statins are a possible option for acute, but not chronic, longstanding AA. Read More

    An Overview of the Biology of Platelet-Rich Plasma and Microneedling as Potential Treatments for Alopecia Areata.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S21-S24
    The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA. Electronic address:
    Platelet-rich plasma and microneedling have been investigated recently as potential therapeutic options for the treatment of hair disorders. Evidence from laboratory studies indicates that these treatments enhance growth factor production that in turn facilitates hair follicle development and cycling. Several small studies and case reports have presented encouraging findings regarding the use of these treatments for alopecia areata. Read More

    Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S18-S20
    Department of Dermatology, New Haven, Connecticut, USA. Electronic address:
    Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Read More

    Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S12-S17
    Department of Dermatology, University of Münster, Münster, Germany.
    The collapse of the immune privilege (IP) of the anagen hair bulb is now accepted as a key element in AA pathogenesis, and hair bulb IP restoration lies at the core of AA therapy. Here, we briefly review the essentials of hair bulb IP and recent progress in understanding its complexity. We discuss open questions and why the systematic dissection of hair bulb IP and its pharmacological manipulation (including the clinical testing of FK506 and α-melanocyte-stimulating hormone analogs) promise to extend the range of future therapeutic options in AA and other IP collapse-related autoimmune diseases. Read More

    Current State of Research and Summary of Preceding Summits.
    J Investig Dermatol Symp Proc 2018 Jan;19(1):S1-S2
    Department of Dermatology, University of Colorado School of Medicine, University of Colorado Denver, Aurora, Colorado, USA. Electronic address:
    During its 25th anniversary year, the National Alopecia Areata Foundation (NAAF) undertook a project to completely re-evaluate their research program and to help focus and direct future directions of alopecia areata (AA) research to better meet the goals of individuals with and the scientists working to discover mechanisms of disease and better treatments for AA. This project was embodied in five research summits in 2008, 2009, 2010, 2012, and 2014 as part of the NAAF's main strategic initiative, the Alopecia Areata Treatment Development Program, to accelerate progress toward a viable treatment. The sixth summit, "Building and Crossing the Translational Bridge," was held in 2016 and highlighted strong clinical data on the efficacy of topical and oral JAK inhibitors in mouse models and human AA. Read More

    "i hair": A prognostic marker in alopecia areata & trichotillomania.
    Indian J Dermatol 2017 Nov-Dec;62(6):658-660
    Department of Dermatology, Rita Skin Foundation, Kolkata, West Bengal, India.
    Trichoscopy as an investigative tool is revolutionizing the diagnosis of hair disorders. The use of a trichoscope has unveiled a plethora of signs which not only helps in decoding the underlying tricoscopic condition but also acts as prognostic markers. Herein, we present a new trichoscopic sign, "i hair" in alopecia areata and trichotillomania. Read More

    Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Am J Clin Dermatol 2017 Dec 18. Epub 2017 Dec 18.
    Oncodermatology, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
    The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune related [immune-related adverse events (irAEs)], notably mediated by the triggering of cytotoxic CD4+/CD8+ T cell activation. Read More

    A review of monochromatic light devices for the treatment of alopecia areata.
    Lasers Med Sci 2018 Feb 17;33(2):435-444. Epub 2017 Dec 17.
    Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Ave., RMSB 2023, Miami, FL, 33136, USA.
    There are many laser technologies that are being tested that claim to support hair regrowth for patients with alopecia areata (AA). In this paper, we will determine whether the body of evidence supports the use of devices using monochromatic light sources to treat AA. Articles were gathered from PubMed, Embase, and the Cochrane database using these keywords: lasers, excimer laser, low-level laser therapy (LLLT), low-level light therapy, alopecia, alopecia areata, and hair loss with a category modifier of English. Read More

    [What's new in dermatological treatment?]
    Ann Dermatol Venereol 2017 Dec;144 Suppl 4:IVS47-IVS53
    Service de dermatologie, hôpital Robert-Debré, Reims, France. Electronic address:
    On a therapeutic point of view, 2017 in dermatology could be summarized in one disease, one pathway and in one number : atopic dermatitis, JAK inhibitors and 23. 2017 will be the year of the first registration of a biologic treatment in atopic dermatitis, dupilumab, with numerous other drugs currently in development. JAK inhibitors show promising results in several difficult-to-treat conditions, such as alopecia areata, vitiligo or atopic dermatitis, but still warrant confirmation in upcoming controlled trials. Read More

    [What's new in pediatric dermatology?]
    Ann Dermatol Venereol 2017 Dec;144 Suppl 4:IVS29-IVS39
    Centre de référence des maladies rares de la peau et des muqueuses d'origine génétique, service de dermatologie, hôpital Archet 2, CHU de Nice, France. Electronic address:
    The year 2017 in pediatric dermatology was marked by several consensus recommendations and meta analyzes on childhood psoriasis, atopic dermatitis or PHACE syndrome, case series on the role of anti-JAK treatment in adolescent with alopecia areata, sirolimus for vascular malformations, ivermectine for rosacea, inhibitors of MEK for type 1 neurofibromatosis or on the side effects of the oral isotretinoin for acne or propranolol for immature hemangioma. Only few randomized controlled studies have been published on the interest of adalimumab in the treatment of psoriasis or topical sirolimus for angiofibroma in tuberous sclerosis complex for example. There were also clinical articles on various affections such as the sign of the scalp hair collar sign, childhood prurigo, ichthyosis, atopic dermatitis, warts or Zika virus infection. Read More

    Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm.
    Int J Dermatol 2018 Feb 15;57(2):217-222. Epub 2017 Dec 15.
    Department of Dermatology Venereology and Leprology, PGIMER, Chandigarh, India.
    Background: Vitamin D (Vit.D) deficiency has been reported in alopecia areata (AA). Downregulation of Vitamin D receptor (VDR) on hair follicles is associated with reduced hair growth. Read More

    1 OF 77